ELDN
Eledon Pharmaceuticals Inc
NASDAQ: ELDN · HEALTHCARE · BIOTECHNOLOGY
$2.76
+14.52% today
Updated 2026-10-28
Market cap
$183.65M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.90
Dividend yield
—
52W range
$1 – $5
Volume
0.9M
WallStSmart proprietary scores
20
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.0
Quality
B3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
-2.8
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →270 stocks currently score above 75
Price targets
Analyst target
$9.00
+226.09%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.01x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -2.83 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-22.68M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-87.97M | $-40.33M | $-36.18M | $-45.62M | $-31.63M |
| EPS | — | — | — | — | $-0.90 |
| Free cash flow | $-28.42M | $-39.53M | $-47.27M | $-62.34M | $-22.68M |
| Profit margin | — | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2035-01-10 | ROBINSON, JAMES A. JR. | Buy | 30,870 | — |
| 2026-01-10 | ROBINSON, JAMES A. JR. | Sale | 3,430 | — |
| 2026-01-10 | ROBINSON, JAMES A. JR. | Buy | 3,430 | — |
Peer comparison
Smart narrative
Eledon Pharmaceuticals Inc trades at $2.76. Our Smart Value Score of 20/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -2.83, it sits in the distress.
Frequently asked questions
What is Eledon Pharmaceuticals Inc's stock price?
Eledon Pharmaceuticals Inc (ELDN) trades at $2.76.
Is Eledon Pharmaceuticals Inc overvalued?
Eledon Pharmaceuticals Inc carries a Smart Value Score of 20/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Eledon Pharmaceuticals Inc (ELDN)?
The 12-month analyst consensus target is $9.00, about 226.1% above the current $2.76. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Eledon Pharmaceuticals Inc's Altman Z-Score is -2.83, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-77.79%
Beta0.85
50D MA$2.84
200D MA$3.08
Shares out0.08B
Float0.07B
Short ratio—
Avg volume0.9M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—